Harrow, Inc. (HROW) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 102.17M USD | Liabilities, Current |
| Cash and equivalents | 83.89M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 118.56M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 16.91M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $102.17M | $83.89M | (m) | $118.56M | $16.91M | (m) |
| 2026-03-31 | (m) | $91.44M | $94.64M | (m) | $101.26M | $16.50M | (m) |
| 2025-12-31 | (m) | $96.30M | $72.93M | (m) | $110.89M | $13.52M | (m) |
| 2025-09-30 | (m) | $65.40M | $74.29M | (m) | $77.60M | $12.83M | (m) |
| 2025-06-30 | (m) | $248.88M | $52.96M | (m) | $78.82M | $11.55M | (m) |
| 2025-03-31 | (m) | $186.99M | $66.73M | (m) | $77.06M | $10.72M | (m) |
| 2024-12-31 | (m) | $91.34M | $47.25M | (m) | $116.37M | $10.70M | (m) |
| 2024-09-30 | (m) | $95.00M | $72.60M | (m) | $53.73M | $10.16M | (m) |
| 2024-06-30 | (m) | $53.55M | $70.97M | (m) | $51.99M | $9.43M | (m) |
| 2024-03-31 | (m) | $41.75M | $68.54M | (m) | $28.96M | $10.81M | (m) |
| 2023-12-31 | (m) | $49.34M | $74.08M | (m) | $36.26M | $10.87M | (m) |
| 2023-09-30 | (m) | $19.03M | $65.61M | (m) | $18.47M | $8.92M | (m) |
| 2023-06-30 | (m) | $23.01M | (m) | (m) | $18.26M | $8.55M | (m) |
| 2023-03-31 | (m) | $17.71M | (m) | (m) | $12.11M | $9.09M | (m) |
| 2022-12-31 | (m) | $18.63M | (m) | (m) | $6.25M | $6.54M | (m) |
| 2022-09-30 | (m) | $18.37M | $44.96M | (m) | $6.74M | $5.28M | (m) |
| 2022-06-30 | (m) | $12.92M | $46.44M | (m) | $6.75M | $5.13M | (m) |
| 2022-03-31 | (m) | $9.18M | $41.95M | (m) | $6.00M | $4.40M | (m) |
| 2021-12-31 | (m) | $9.72M | $42.17M | (m) | $4.47M | $4.22M | (m) |
| 2021-09-30 | (m) | $10.48M | (m) | (m) | $4.16M | $3.92M | (m) |
| 2021-06-30 | (m) | $8.14M | (m) | (m) | $3.71M | $3.90M | (m) |
| 2021-03-31 | (m) | $10.07M | (m) | (m) | $3.25M | $4.50M | (m) |
| 2020-12-31 | (m) | $10.80M | $4.10M | (m) | $2.66M | $3.96M | (m) |
| 2020-09-30 | (m) | $13.78M | (m) | (m) | $2.19M | $3.97M | (m) |
| 2020-06-30 | (m) | $13.08M | (m) | (m) | $2.02M | $3.84M | (m) |
| 2020-03-31 | (m) | $13.22M | (m) | (m) | $2.03M | $3.99M | (m) |
| 2019-12-31 | (m) | $12.28M | (m) | (m) | $2.01M | $3.30M | (m) |
| 2019-09-30 | (m) | $11.43M | (m) | (m) | $2.81M | $2.44M | (m) |
| 2019-06-30 | (m) | $9.86M | (m) | (m) | $2.22M | $2.65M | (m) |
| 2019-03-31 | (m) | $11.21M | (m) | (m) | $2.19M | $2.39M | (m) |
| 2018-12-31 | (m) | $11.90M | (m) | (m) | $1.91M | $1.83M | (m) |
| 2018-09-30 | (m) | $10.37M | (m) | (m) | $1.73M | $2.52M | (m) |
| 2018-06-30 | (m) | $8.16M | (m) | (m) | $1.36M | $2.22M | (m) |
| 2018-03-31 | (m) | $5.90M | (m) | (m) | $1.47M | $2.04M | (m) |
| 2017-12-31 | (m) | $5.77M | $4.02M | (m) | $1.53M | $2.25M | (m) |
| 2017-09-30 | (m) | $6.05M | $3.87M | (m) | $2.63M | $2.37M | (m) |
| 2017-06-30 | (m) | $5.52M | $4.17M | (m) | $2.86M | $1.83M | (m) |
| 2017-03-31 | (m) | $11.79M | $7.40M | (m) | $3.04M | $2.04M | (m) |
| 2016-12-31 | (m) | $9.90M | $8.85M | (m) | $2.92M | $1.84M | (m) |
| 2016-09-30 | (m) | $5.78M | $2.36M | (m) | $2.23M | $1.90M | (m) |
| 2016-06-30 | (m) | $5.33M | $5.44M | (m) | $1.92M | $1.44M | (m) |
| 2016-03-31 | (m) | $5.67M | $11.82M | (m) | $943.00K | $1.23M | (m) |
| 2015-12-31 | (m) | $5.37M | $2.69M | (m) | $840.00K | $1.41M | (m) |
| 2015-09-30 | (m) | $3.74M | $6.56M | (m) | $701.00K | $1.27M | (m) |
| 2015-06-30 | (m) | $2.67M | $10.05M | (m) | $579.00K | $793.00K | (m) |
| 2015-03-31 | (m) | $2.24M | $2.90M | (m) | $436.00K | $711.00K | (m) |
| 2014-12-31 | (m) | $1.56M | $8.21M | (m) | $81.32K | $372.74K | (m) |
| 2014-09-30 | (m) | $1.58M | $10.36M | (m) | $68.31K | $351.20K | (m) |
| 2014-06-30 | (m) | $1.34M | $12.10M | (m) | $81.15K | $172.75K | (m) |
| 2014-03-31 | (m) | $655.47K | $14.20M | (m) | $1.41K | (m) | (m) |
| 2013-12-31 | (m) | $650.63K | $15.58M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $1.06M | $16.83M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $1.11M | $17.97M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $848.55K | $18.98M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $709.56K | $10.04M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $669.84K | $10.99M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $491.20K | $7.72M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $930.50K | $146.71K | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $1.86M | $146.16K | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $1.65M | $2.15K | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $1.60M | $5.55K | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $70.87K | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $335.04K | $291.46K | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $467.28K | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $1.04M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.59M | (m) | (m) | (m) | (m) |
| 1998-07-23 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |